A causal link between pandemic influenza vaccine and narcolepsy has been appreciated for several years. A retrospective multicenter case-control study by Oberle et al showed an increased risk for narcolepsy after receiving this vaccine, and other researchers reported a strong association with class II HLA allele DQB1*06:01 [7]. Although the characteristics of influenza vaccine differ from those of HPV vaccination, narcolepsy has been recognized as having an immune-mediated component in its pathogenesis. Perhaps other immune-mediated and/or neuropsychiatric phenomena might also be related to yet undefined genetic predispositions and be promoted by gene-environment interactions [8]. Well-defined patient cohorts like those described by Huang et al could be an important source of such information during investigations of potential links of HLA types with SAEs and other medical conditions. This might exclude any association between HPV vaccines and suspected postvaccination phenomena or, in contrast, might provide evidence of the roles of genetic and personal factors (eg, family and disease history) in vaccine safety.

HPV immunization induced serological conversion in >80% of human immunodeficiency virus (HIV)–infected adolescents and young adults; moreover, HIV-infected patients showed a persistence of protective antibodies over 1 year after the first dose, which was comparable to that in healthy controls. Interestingly, hepatitis B vaccine, which is produced by the same DNA recombinant technology as HPV vaccine, has been reported to elicit protective antibodies in only 20%–70% of HIV-positive individuals [9, 10]. Such a simple observation could be used as additional evidence of the remarkable immunogenicity of HPV vaccines. Reduction of the HPV vaccine schedule to 2 doses, with a greater interval between doses, may be a useful advance in national vaccine programs.

Note

Potential conflicts of interest. The author: No reported conflicts of interest.

The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Dimitri Peddighe

1Department of Pediatrics, ASST Melegnano eMartesana, Vizzolo Predabissi, Milano, and 2Department of Pediatrics, Università degli Studi di Pavia, Pavia, Italy

References

1. Huang LM, Puthanakit T, Cheng-Hsun C, et al. Sustained immunogenicity of 2-dose human papillomavirus 16/18 AS04-adjuvanted vaccine schedules in girls aged 9–14 years: a randomized trial. J Infect Dis 2015; 215:1711–9.
2. Pellegrino P, Carnovale C, Pozzi M, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev 2014; 13:736–41.
3. Peddighe D, Castelli L, Marseglia GL, Bruni P. A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvanted vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? Immunol Res 2014; 60:236–46.
4. Palmieri B, Peddighe D, Vadala M, Laurino C, Carnovale C, Clementi E. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. Immunol Res 2017; 65:106–16.
5. Kinoshita T, Abe RT, Hineno A, Tsunekawa K, Nakane S, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med 2014; 53:2185–200.
6. Aratani S, Fujita H, Kuroiwa Y, et al. Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxin. Sci Rep 2016; 6:36943.
7. Oberle D, Pavel J, Mayer G, Geisler P, Keller-Stanislawski B; German Narcolepsy Study Group. Retrospective multicenter matched case-control study on the risk factors for narcolepsy with special focus on vaccinations (including pandemic influenza vaccination) and infections in Germany. Sleep Med 2017; 34:71–83.
8. Bomfim IL, Lamb F, Fink K, et al. The immunogenetics of narcolepsy associated with A(H1N1)pdm09 vaccination (Pandemrix) supports a potent gene-environment interaction. Genes Immun 2017; 18:75–81.
9. Toft L, Storgaard M, Müller M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 2014; 209:1165–73.
10. van den Berg R, van Hoogstraten I, van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev 2009; 11:157–64.

Received 15 June 2017; editorial decision 24 July 2017; accepted 14 August 2017; published online September 6, 2017.

Correspondence: D. Peddighe, MD, Department of Pediatrics, ASST Melegnano e Martesana, via Pandina 1, Vizzolo Predabissi (MI), Italy (dimimdpv@yahoo.it).

The Journal of Infectious Diseases® 2017;216:782–3
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/infdis/jix364

Reply to Peddighe

To THE EDITOR—We thank Peddighe for the critical review of our article related to the immunogenicity and safety of the AS04-adjuvanted human papillomavirus (HPV) type 16/18 (AS04-HPV-16/18) vaccine, given as 2-dose schedules and compared to a 3-dose schedule, and for his questions related to the safety of HPV vaccine.

The benefit/risk balance of the AS04-HPV16/18 vaccine is under constant evaluation by the Company through close monitoring of adverse event (AE)
reports following vaccination allowing assessment of potential risk associated with vaccination. Various strategies are used, which include the long-term follow-up of cohorts vaccinated in clinical trials, pooling of clinical trials data, post-marketing surveillance of safety and clinical outcomes, and review of large health databases to enable signal detection [1]. As the AS04-HPV-16/18 vaccine is adjuvanted, the potential to develop autoimmune diseases is a theoretical concern. Consequently, the analysis of potentially immune-mediated diseases (pIMDs) is of particular interest.

A pooled analysis of the safety data from the GSK clinical trial development program (57,580 subjects and 96,704 vaccine doses) concluded that the incidence and distribution of AEs were similar among vaccine and control groups [2]. The rates of pIMD between groups were also similar, with no patterns in the specific syndrome reported or the time to onset. Similarly, an analysis of postlicensure safety data of >4 years of routine clinical practice identified no safety concerns from general AE reports, or from reports of pIMDs [3]. An observational cohort study in female subjects aged 9–25 years did not show evidence of an increased risk of autoimmune disease following vaccination with AS04-HPV-16/18 vaccine [4]. More recently, several analyses looking at specific AEs of potential interest after HPV vaccination implementation and conducted by independent institutions have been published and have come to similar conclusions [5–9].

In the study by Huang et al, all subjects received the AS04-HPV-16/18 vaccine. Medically significant conditions, defined as AEs prompting emergency room or physician visits with the exception of routine visits or common diseases, were to be reported throughout the study. Analysis of the 374 reported medically significant conditions did not reveal any event or cluster of events of potential concern. Serious AEs (SAEs) were reported by 72 participants, none of which were fatal. Appendicitis was the most frequently reported SAE, by 8 subjects. Most SAEs were reported only once per group. The pIMD case of systemic erythematous lupus (SLE) described by Huang et al was assessed as causally related to vaccination by the investigator while the study was ongoing. The exact time to onset of the symptoms is unclear. The patient had right knee pain from an unspecified date and received a diagnosis of transient synovitis 6 months after first vaccination. A diagnosis of SLE was obtained almost 2 years after the initial vaccination. Retrospectively, the case did not fully meet criteria for SLE [10] and could not be confirmed on the basis of available information. Of interest, a recent study investigated the risk of SLE in vaccinated subjects (most of whom received non-HPV vaccines) and did not make conclusions regarding vaccine causality [11]. The second event of interest described by Huang et al, celiac disease, was classified as a nonserious event. The diagnosis was made 3 weeks after first vaccination; however, no confirmatory biopsy was performed, to our knowledge. The subject’s recorded medical history suggested preexisting manifestations of the disease. No further information was available, as the subject withdrew from the study shortly after receiving the first dose and did not wish to be recontacted.

In conclusion, the safety data generated in the present study were in line with the known safety profile of the vaccine as described in the current product information [12]. The full clinical study report is available from the GSK clinical trial register website (available at: https://www.gsk-clinicalstudyregister.com), under study ID 114700.

Notes

Acknowledgments. The authors would like to thank Business & Decision Life Sciences platform for editorial assistance and publication coordination, on behalf of GSK. Thibaud André (Business & Decision Life Sciences on behalf of GSK) coordinated the publication development and provided editorial support.

Financial support. This work was supported by GlaxoSmithKline Biologicals SA.

Potential conflicts of interest. N. F., V. B., and L. S. are employees of the GSK group of companies. N. F. and V. B. received restricted shares from the GSK group of companies. L.-M. H. received grants through his institution from the GSK group of companies and also received consultancy fees for participation in the HPV expert board and payment for educational presentation from the GSK group of companies. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Louise Stevenson,1 L.-M. Huang,2 Valérie Berlaimont,1 and Nicolas Folschweiller1

1GSK, Wavre, Belgium; and 2Department of Pediatrics, National Taiwan University Children’s Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

References

1. Angelo M-G, Taylor S, Struyf F, et al. Strategies for continuous evaluation of the benefit-risk profile of human papillomavirus-16/18-AS04-adjuvanted vaccine. Expert Rev Vaccines 2014 (c); 13:1297–306.
2. Angelo M-G, David M-P, Zima J, et al. Pooled analysis of large and long-term safety data from the AS04-adjuvanted human papillomavirus vaccine clinical trial program. Pharmacoepidemiol Drug Saf 2014; 23:466–79.
3. Angelo M-G, Zima J, Tavares da Silva F, Baril L, Arellano F. Postlicensure safety surveillance for AS04-adjuvanted human papillomavirus vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 2014 (b); 23:456–65.
4. Willame C, Rosillon D, Zima J, et al. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18
5. Dray-Spira R. Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France. Presented at: 2016 Eurogin International Multidisciplinary Congress, Salzburg, Austria.

6. Agence nationale de sécurité du médicament et des produits de santé (ANSM study). Vaccins anti-HPV et risque de maladies autoimmunes: étude pharmacoépidémiologique; 2015. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Vaccination-contre-les-infections-a-HPV-et-risque-de-maladies-autoimmunes-une-etude-Cnamts-ANSM-rassurante-Point-d-information. Accessed 4 July 2017.

7. Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: a self-controlled case-series study in England. Vaccine 2017; 35:1729–32.

8. Cameron RL, Ahmed S, Pollock KG. Adverse event monitoring of the human papillomavirus vaccines in Scotland. Intern Med J 2016; 46:452–7.

9. Feiring B, Laake I, Bakken IJ, et al. HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: a nationwide register-based study from Norway. Vaccine 2017; 35:4203–12.

10. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677–86.

11. Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, et al.; PGRx-AD Study Group. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. J Autoimmun 2017; 79:84–90.

12. Cervarix European product information. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125. Accessed 4 July 2017.